These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 34610388)

  • 1. The Clinical Cell-Cycle Risk (CCR) Score Is Associated With Metastasis After Radiation Therapy and Provides Guidance on When to Forgo Combined Androgen Deprivation Therapy With Dose-Escalated Radiation.
    Tward J; Lenz L; Flake DD; Rajamani S; Yonover P; Olsson C; Kapoor DA; Mantz C; Liauw SL; Antic T; Fabrizio M; Salzstein D; Shore N; Albertson D; Henderson J; Lee SP; Gay HA; Michalski J; Hung A; Raben D; Garraway I; Lewis MS; Nguyen PL; Marshall DT; Brawer MK; Stone S; Cohen T
    Int J Radiat Oncol Biol Phys; 2022 May; 113(1):66-76. PubMed ID: 34610388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Personalizing Localized Prostate Cancer: Validation of a Combined Clinical Cell-cycle Risk (CCR) Score Threshold for Prognosticating Benefit From Multimodality Therapy.
    Tward JD; Schlomm T; Bardot S; Canter DJ; Scroggins T; Freedland SJ; Lenz L; Flake DD; Cohen T; Brawer MK; Stone S; Bishoff J
    Clin Genitourin Cancer; 2021 Aug; 19(4):296-304.e3. PubMed ID: 33608228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using the Cell-Cycle Risk Score to Predict the Benefit of Androgen-Deprivation Therapy Added to Radiation Therapy in Patients With Newly Diagnosed Prostate Cancer.
    Tward JD; Lenz L; Gutin A; Clegg W; Kasten CR; Finch R; Cohen T; Michalski J; Kishan AU
    JCO Precis Oncol; 2024 May; 8():e2300722. PubMed ID: 38748970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy.
    Dong Y; Ruth KJ; Churilla TM; Viterbo R; Sobczak ML; Smaldone MC; Chen DY; Uzzo RG; Hallman MH; Horwitz EM
    Can J Urol; 2017 Feb; 24(1):8656-8662. PubMed ID: 28263132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the effectiveness of adding androgen deprivation to modern dose-escalated radiotherapy for men with favorable intermediate-risk prostate cancer.
    Falchook AD; Basak R; Mohiuddin JJ; Chen RC
    Cancer; 2016 Aug; 122(15):2341-9. PubMed ID: 27191936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Large institutional variations in use of androgen deprivation therapy with definitive radiotherapy in a population-based cohort of men with intermediate- and high-risk prostate cancer.
    Ong WL; Foroudi F; Evans S; Millar J
    BJU Int; 2017 Nov; 120 Suppl 3():35-42. PubMed ID: 28749017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is androgen deprivation therapy necessary in all intermediate-risk prostate cancer patients treated in the dose escalation era?
    Castle KO; Hoffman KE; Levy LB; Lee AK; Choi S; Nguyen QN; Frank SJ; Pugh TJ; McGuire SE; Kuban DA
    Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):693-9. PubMed ID: 22836052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective evaluation reveals that long-term androgen deprivation therapy improves cause-specific and overall survival in the setting of dose-escalated radiation for high-risk prostate cancer.
    Feng FY; Blas K; Olson K; Stenmark M; Sandler H; Hamstra DA
    Int J Radiat Oncol Biol Phys; 2013 May; 86(1):64-71. PubMed ID: 23462420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the Prognostic Utility of the Cell Cycle Progression Score for Predicting Clinical Outcomes in African American and Non-African American Men with Localized Prostate Cancer.
    Canter DJ; Reid J; Latsis M; Variano M; Halat S; Rajamani S; Gurtner KE; Sangale Z; Brawer M; Stone S; Bardot S
    Eur Urol; 2019 Mar; 75(3):515-522. PubMed ID: 30391079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequencing of Androgen-Deprivation Therapy of Short Duration With Radiotherapy for Nonmetastatic Prostate Cancer (SANDSTORM): A Pooled Analysis of 12 Randomized Trials.
    Ma TM; Sun Y; Malone S; Roach M; Dearnaley D; Pisansky TM; Feng FY; Sandler HM; Efstathiou JA; Syndikus I; Hall EC; Tree AC; Sydes MR; Cruickshank C; Roy S; Bolla M; Maingon P; De Reijke T; Nabid A; Carrier N; Souhami L; Zapatero A; Guerrero A; Alvarez A; Gonzalez San-Segundo C; Maldonado X; Romero T; Steinberg ML; Valle LF; Rettig MB; Nickols NG; Shoag JE; Reiter RE; Zaorsky NG; Jia AY; Garcia JA; Spratt DE; Kishan AU;
    J Clin Oncol; 2023 Feb; 41(4):881-892. PubMed ID: 36269935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic Classifier for Guiding Treatment of Intermediate-Risk Prostate Cancers to Dose-Escalated Image Guided Radiation Therapy Without Hormone Therapy.
    Berlin A; Murgic J; Hosni A; Pintilie M; Salcedo A; Fraser M; Kamel-Reid S; Zhang J; Wang Q; Ch'ng C; Deheshi S; Davicioni E; van der Kwast T; Boutros PC; Bristow RG; Chua MLK
    Int J Radiat Oncol Biol Phys; 2019 Jan; 103(1):84-91. PubMed ID: 30170099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continued benefit to androgen deprivation therapy for prostate cancer patients treated with dose-escalated radiation therapy across multiple definitions of high-risk disease.
    Stenmark MH; Blas K; Halverson S; Sandler HM; Feng FY; Hamstra DA
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e335-44. PubMed ID: 21645976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of adding androgen deprivation therapy to permanent iodine-125 implantation with or without external beam radiation therapy on the outcomes in patients with intermediate-risk prostate cancer: A propensity score-matched analysis.
    Sutani S; Yorozu A; Toya K; Shiraishi Y; Nishiyama T; Yagi Y; Nakamura K; Saito S
    Brachytherapy; 2021; 20(1):10-18. PubMed ID: 33069598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short-term ADT and Dose-escalated IMRT in Patients With Intermediate-risk Prostate Cancer: Benefit or Caution?
    Post CM; Kahn JM; Turina CB; Beer TM; Hung AY
    Am J Clin Oncol; 2022 May; 45(5):190-195. PubMed ID: 35446278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic capabilities and clinical utility of cell cycle progression testing, prostate imaging reporting and data system, version 2, and clinicopathologic data in management of localized prostate cancer.
    Morris DS; Woods JS; Edwards B; Lenz L; Logan J; Flake DD; Mabey B; Bishoff JT; Cohen T; Stone S
    Urol Oncol; 2021 Jun; 39(6):366.e19-366.e28. PubMed ID: 33257218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjusting the duration of androgen deprivation therapy (ADT) based on nadir PSA for high risk localized prostate cancer patients treated with definitive external beam radiation therapy and ADT.
    Ayoub Z; Khader J; Bulbul M; Khauli RB; Andraos TY; Shamseddine A; Mukherji D; Geara FB
    BMC Urol; 2022 Dec; 22(1):204. PubMed ID: 36503556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation of the Combined Clinical Cell-Cycle Risk Score to Prognosticate Early Prostate Cancer Metastasis From Biopsy Specimens and Comparison With Other Routinely Used Risk Classifiers.
    Hutten RJ; Odei B; Johnson SB; Tward JD
    JCO Precis Oncol; 2024 Feb; 8():e2300364. PubMed ID: 38330260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utilization of biopsy-based genomic classifier to predict distant metastasis after definitive radiation and short-course ADT for intermediate and high-risk prostate cancer.
    Nguyen PL; Martin NE; Choeurng V; Palmer-Aronsten B; Kolisnik T; Beard CJ; Orio PF; Nezolosky MD; Chen YW; Shin H; Davicioni E; Feng FY
    Prostate Cancer Prostatic Dis; 2017 Jun; 20(2):186-192. PubMed ID: 28117383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival outcomes of radiotherapy with or without androgen-deprivation therapy for patients with intermediate-risk prostate cancer using the National Cancer Data Base.
    Amini A; Rusthoven CG; Jones BL; Armstrong H; Raben D; Kavanagh BD
    Urol Oncol; 2016 Apr; 34(4):165.e1-9. PubMed ID: 26699831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereotactic body radiotherapy versus conventional/moderate fractionated radiation therapy with androgen deprivation therapy for unfavorable risk prostate cancer.
    Patel SA; Switchenko JM; Fischer-Valuck B; Zhang C; Rose BS; Chen RC; Jani AB; Royce TJ
    Radiat Oncol; 2020 Sep; 15(1):217. PubMed ID: 32933541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.